Achieve®与Marquee®两种不同空心活检针的临床疗效、主观使用者体验与安全性比较
回顾性比较18G非靶向肝穿刺活检中Achieve®(30例)与Marquee®(30例)的标本质量及放射科医师主观评分,并检索2017年1月1日至2020年9月30日全部肝穿刺病例比较出血并发症。Marquee®标本最大宽度显著更大(0.85 mm vs 0.78 mm,p<0.01),放射科医师在多项触觉指标上更偏好Marquee®;800例中主要与次要出血并发症率无显著差异。
要点
- Marquee®肝穿刺标本最大宽度显著大于Achieve®(0.85 mm vs 0.78 mm,p<0.01)。
- 标本总长度与门管区数目在两种针间无显著差异。
- 放射科医师在cocking、chamber exposure和整体评分上更偏好Marquee®(各项p<0.02)。
核心结论
- Marquee®较Achieve®肝穿刺标本显著更宽,放射科医师在多项触觉指标上更偏好Marquee®,主要并发症率无显著差异;两者均为侧切槽设计,Marquee®标本质量与使用者偏好更优且未牺牲安全性。
研究设计与样本
- 回顾性研究:连续30例Achieve®(Merit Medical)与30例Marquee®(BD Bard)18G非靶向肝穿刺活检,由对针型盲态的病理医师评估标本;16名放射科医师以1–5分主观评分;另检索2017年1月1日至2020年9月30日全部(靶向与非靶向)肝穿刺活检共800例比较出血并发症率;组间比较采用t检验。
诊断标准与关键数值
- Achieve® vs Marquee®:标本总长度均值(SD)29.7(7.0)mm vs 31.9(4.6)mm,p=0.1;最大宽度0.78(0.1)mm vs 0.85(0.1)mm,p<0.01;门管区数目15.3(5.3)vs 17.3(5.3),p=0.2。
临床应用与阅片要点
- 放射科医师在cocking、chamber exposure和整体评分上更偏好Marquee®(各项p<0.02),两种针在firing、recoil和handling评分相似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare clinical efficacy, subjective radiologist preference, and complication rates for two different core biopsy needles, the Achieve® and Marquee®.
METHODS: Retrospective review included consecutive patients who underwent 18 gauge non-targeted core liver biopsy, 30 with Achieve® (Merit Medical) and 30 with Marquee® (BD Bard) Pathologist (blinded to needle type) reviewed specimen total length, maximum width, and portal triad count. Sixteen radiologists subjectively rated (1 to 5(best)) each needle for cocking, firing, recoil, chamber exposure, handling, and overall. A medical records search of all (targeted and non-targeted) core liver biopsies 1/1/17-9/30/2020 compared rates of major (requiring transfusion and/or embolization) and minor (self-limited bleeding) hemorrhagic complications. Comparison between needle types was performed using t-test.
RESULTS: For Achieve® and Marquee® needles, the respective mean (SD) for total length(mm) was 29.7(7.0) and 31.9(4.6), p = 0.1; max width(mm) was 0.78(0.1) and 0.85(0.1), p < 0.01; and number of portal triads was 15.3(5.3) and 17.3(5.3), p = 0.2. Radiologists subjectively preferred the Marquee® for several measures including cocking, chamber exposure, and overall (p < 0.02 for each), while the needles were rated similarly for firing, recoil, and handling. Review of 800 cases showed no difference in major (1.0% Achieve®, 1.9% Marquee®, p = 0.5) or minor (1.5% Achieve®, 0.5% Marquee®, p = 0.3) rates of hemorrhagic complications.
CONCLUSION: Liver biopsy specimens were significantly wider with Marquee® compared to Achieve®. Radiologists preferred the Marquee® for multiple tactile measures, while the major complication rate was not significantly different. While both needles have a similar side-notch design, the Marquee® needle demonstrates better sample quality and higher user preference, without compromising safety.
引用
- Ho LM, Pendse AA, Ronald J, et al. Comparison of clinical efficacy, subjective user experience, and safety for two different core biopsy needles, the Achieve® and Marquee®. Abdom Radiol (NY). 2021. PMID: 34181039. doi:10.1007/s00261-021-03187-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。